Tirzepatide — Dual GIP / GLP-1 Receptor Co-Agonist Research Review

This article is for informational and educational purposes only and does not constitute medical advice. Tirzepatide is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.

Wholesale Peps is not affiliated with, endorsed by, or in any way connected to Eli Lilly and Company. This research review is compiled from publicly available peer-reviewed literature for educational purposes only.

Research Summary

Tirzepatide is an acylated synthetic peptide engineered to co-activate two incretin receptors simultaneously: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). As the first approved dual incretin receptor agonist, it occupies a distinct pharmacological position between GLP-1 monoagonists and newer triple-receptor compounds. Published phase 3 trials reported substantial dose-dependent reductions in body weight in adults with obesity (SURMOUNT-1) and superior glycemic reduction compared with semaglutide 1 mg in a direct head-to-head trial (SURPASS-2). Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023). Cardiovascular outcomes trial data and the mechanistic contribution of GIPR agonism to observed weight loss both represent active areas of ongoing research. All referenced data derive from human clinical trials; in vitro applications are for receptor pharmacology and mechanistic research.

1. Background

1.1 The GIP Receptor and an Unexpected Finding

Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted by K-cells in the proximal small intestine in response to nutrient ingestion. Like GLP-1, it potentiates glucose-stimulated insulin secretion from pancreatic beta cells and contributes to the postprandial incretin effect. However, earlier research characterizing the GIP receptor (GIPR) in metabolic contexts suggested that GIPR agonism alone had limited or neutral effects on body weight, and some preclinical data suggested it might even attenuate the weight-reducing effects of GLP-1R agonism [1].

The development of tirzepatide challenged this assumption. Rather than blunting GLP-1R-mediated weight loss, combined GIPR and GLP-1R co-agonism produced weight reductions that exceeded those observed with GLP-1R monoagonism alone in clinical comparisons. The mechanistic explanation for this finding — whether GIPR agonism acts synergistically with GLP-1R in adipose tissue, the central nervous system, or both — remains an active area of investigation [1].

1.2 From GLP-1 Monoagonism to Dual Incretin Co-Agonism

First-generation GLP-1 receptor agonists — including exenatide (2005), liraglutide (2010), and semaglutide (2017) — established GLP-1R as a validated target for glycemic control and, at higher doses, weight management. Tirzepatide extended this framework by incorporating simultaneous GIPR agonism into a single molecule, representing the first approved compound in the dual incretin receptor agonist class. Its clinical approval preceded the still-investigational triple-receptor compound retatrutide, which adds glucagon receptor (GCGR) agonism to the dual incretin profile.

1.3 Development of Tirzepatide

Tirzepatide was developed by Eli Lilly and Company and received FDA approval in May 2022 under the brand name Mounjaro for glycemic control in adults with type 2 diabetes. A separate FDA approval for chronic weight management in adults with obesity or overweight accompanied by at least one weight-related comorbidity was granted under the brand name Zepbound in November 2023.

Wholesale Peps is not affiliated with, endorsed by, or associated with Eli Lilly and Company.

2. Molecular Structure and Pharmacokinetics

Tirzepatide is a 39-amino acid synthetic peptide. Its backbone is derived from a GIP sequence with modifications that confer GLP-1R agonist activity alongside native-like GIPR activity. Three key structural features define its pharmacological profile:

Table 1 — Key Structural Features of Tirzepatide
Feature	Detail	Pharmacological Purpose
Position 2 substitution	Alpha-aminoisobutyric acid (Aib)	Confers resistance to DPP-4-mediated N-terminal cleavage; extends metabolic half-life
C20 fatty diacid acylation	C20 diacid via γ-glutamic acid spacer at Lys₂₆	High-affinity albumin binding; reduces renal clearance; extends half-life to ~5 days
GIP backbone with GLP-1R activity	39 aa GIP-derived sequence with residues optimized for dual receptor activity	Enables simultaneous co-agonism at both GIPR and GLP-1R from a single molecule

The molecular weight of tirzepatide is approximately 4,814 Da. The C20 fatty diacid chain at lysine-26, attached via a γ-glutamic acid spacer, enables reversible albumin binding and produces a half-life of approximately 5 days — sufficient for once-weekly subcutaneous dosing [2]. Tirzepatide is dosed via once-weekly subcutaneous injection with a standard escalation protocol from 2.5 mg over 20 weeks to reach maintenance doses of 5 mg, 10 mg, or 15 mg.

Tirzepatide has been characterized as an “imbalanced” dual agonist, exhibiting higher potency at GIPR than at GLP-1R in cAMP-based in vitro assays. Additionally, receptor pharmacology studies have described it as a “biased” agonist at GIPR, activating downstream pathways in a pattern that differs from native GIP. The functional significance of this imbalance and bias in determining the compound’s clinical effects has not been definitively established [1].

3. Mechanism of Action

Tirzepatide acts as a co-agonist at two class B G protein-coupled receptors: the GIPR and the GLP-1R, both of which signal primarily through Gs-mediated cyclic AMP (cAMP) accumulation. The four principal mechanistic actions and their proposed contributions to the compound’s metabolic profile are summarized below.

Target 1 — GIPR

GIP Receptor Activation

GIPR activation in pancreatic beta cells potentiates glucose-stimulated insulin secretion in a glucose-dependent manner. GIPR is also expressed in adipose tissue, where agonism has been proposed to promote lipid uptake, adipocyte function, and substrate storage. How these adipose tissue effects relate to net weight outcomes when combined with GLP-1R agonism remains incompletely understood and is the subject of ongoing mechanistic research.

Target 2 — GLP-1R

GLP-1 Receptor Activation

GLP-1R activation drives the same pathways established across the GLP-1 agonist class: glucose-dependent insulin secretion, glucagon suppression in pancreatic alpha cells, delayed gastric emptying via vagal afferents, and central appetite suppression through hypothalamic and brainstem GLP-1R circuits. These effects are well-characterized from the semaglutide and liraglutide literature and are considered the established mechanistic foundation of GLP-1R agonism.

Combined Effect

Synergistic Metabolic Activity

The clinical observation that dual GIPR/GLP-1R co-agonism produces greater weight loss than GLP-1R monoagonism alone suggests that GIPR engagement adds mechanistic value beyond simple additive effects. Proposed explanations include GIPR-mediated amplification of central satiety signaling, direct adipose tissue effects, and enhancement of GLP-1R-mediated pathways through receptor cross-talk. None of these mechanisms has been definitively established as the primary driver in controlled human studies.

Safety Feature

Glucose-Dependent Insulin Release

Both GLP-1R and GIPR drive insulin secretion in a glucose-dependent manner — significant insulin release occurs only when blood glucose is elevated. This shared property limits hypoglycemia risk under monotherapy dosing conditions. The glucose-dependence of tirzepatide's insulinotropic effects is considered one of its safety advantages relative to insulin or sulfonylurea-based therapies in type 2 diabetes management.

4. Receptor Binding Profile

The following table summarizes the approximate in vitro receptor potency profile of tirzepatide alongside semaglutide and native GIP/GLP-1 for reference. Values reflect cAMP accumulation assay data and should not be extrapolated directly to in vivo potency rankings, where albumin binding, tissue distribution, and receptor expression patterns modulate effective concentrations.

Table 2 — Approximate Receptor Potency Profile (In Vitro cAMP Assay)
Compound	GIPR Activity	GLP-1R Activity	GCGR Activity	Class
Native GIP	Full agonist	Inactive	Inactive	Endogenous incretin
Native GLP-1	Inactive	Full agonist	Inactive	Endogenous incretin
Semaglutide	Inactive	Full agonist	Inactive	GLP-1 monoagonist
Tirzepatide	Biased agonist (high potency)	Partial agonist (lower potency)	Inactive	Dual co-agonist
Retatrutide	Agonist	Agonist	Agonist	Triple co-agonist

Willard et al. (2020) characterized tirzepatide as imbalanced — with approximately 5-fold greater potency at GIPR than at GLP-1R in cAMP assays — and as biased at GIPR, activating downstream pathways in a manner that differs from native GIP stimulation. Whether this receptor-level profile translates to distinct clinical effects relative to a balanced dual agonist has not been tested in a controlled comparative trial [1].

5. Key Research Findings

5.1 Type 2 Diabetes — SURPASS Program

The SURPASS (Tirzepatide Once Weekly as Add-on to Metformin in T2D) program evaluated subcutaneous tirzepatide (5 mg, 10 mg, 15 mg weekly) across five phase 3 trials in adults with type 2 diabetes, comparing it against placebo and active comparators including semaglutide 1 mg, insulin degludec, insulin glargine, and dulaglutide.

Across the SURPASS trials, tirzepatide consistently demonstrated dose-dependent reductions in HbA1c of approximately 1.9–2.6 percentage points from baseline, accompanied by body weight reductions of approximately 7–12 kg as a secondary outcome in T2D populations. These glycemic and weight outcomes were reported to exceed those of all active comparators studied in the SURPASS program [2].

Table 3 — SURPASS-2: Tirzepatide vs. Semaglutide 1 mg at 40 Weeks (Frías et al., 2021)
Outcome	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg	Semaglutide 1 mg
HbA1c change (pp)	−1.94	−2.01	−2.30	−1.86
Body weight change	−7.8 kg	−9.3 kg	−11.2 kg	−5.7 kg
HbA1c <7.0%	82%	80%	86%	79%
HbA1c ≤6.5%	63%	69%	75%	56%

SURPASS-2 is notable as a direct head-to-head trial against a GLP-1 monoagonist in the same T2D population, providing within-trial comparative data unavailable for most agents in this class. It should be noted that the comparator dose was semaglutide 1 mg — the T2D dose — rather than the higher 2.4 mg obesity dose; this distinction is relevant when interpreting weight outcome comparisons across trials.

5.2 SURPASS-4: T2D with High Cardiovascular Risk

SURPASS-4 compared tirzepatide with insulin glargine in adults with type 2 diabetes at high cardiovascular risk (n=2,002). Tirzepatide 5–15 mg was associated with greater HbA1c reduction and body weight loss than titrated insulin glargine at 52 weeks. All three tirzepatide dose groups achieved non-inferiority for the composite cardiovascular safety endpoint, with a hazard ratio for MACE of 0.74 (95% CI 0.51–1.08) — a directionally favorable point estimate that did not reach statistical significance in this safety-powered trial [6].

5.3 Obesity / Weight Management — SURMOUNT Program

The SURMOUNT (Tirzepatide Once Weekly as Add-on to Lifestyle Intervention) program evaluated tirzepatide 5 mg, 10 mg, and 15 mg weekly for chronic weight management across five phase 3 trials. The program enrolled adults with obesity or overweight, with and without type 2 diabetes, at trial durations of 72 weeks or longer.

Table 4 — SURMOUNT Program Design Overview
Trial	n	Population	Comparator	Duration
SURMOUNT-1	2,539	Obesity (no T2D)	Placebo	72 weeks
SURMOUNT-2	938	Obesity + T2D	Placebo	72 weeks
SURMOUNT-4	670	Obesity (no T2D), 36-week run-in completed	Switch to placebo	52-week randomized extension

5.4 Weight Loss Outcomes

SURMOUNT-1 (Jastreboff et al., 2022) was the primary efficacy study for the obesity indication. Participants receiving tirzepatide 15 mg experienced an estimated mean body weight reduction of −20.9% at 72 weeks compared with −3.1% with placebo — a treatment difference of −17.8 percentage points [3]. Approximately 55.8% of participants in the 15 mg group achieved ≥20% body weight loss, and 89.5% achieved ≥5% weight loss. Weight loss showed a dose-dependent pattern across all three active doses.

Figure 1 — Approximate Mean % Body Weight Change at 72 Weeks — SURMOUNT-1

Approximate mean percent body weight change from baseline at 72 weeks by dose group (SURMOUNT-1, adults with obesity without T2D). Values estimated from Jastreboff et al., 2022 [3]. Verify exact figures from source publication.

Table 5 — SURMOUNT-1 and SURMOUNT-2 Weight Loss Outcomes Summary
Trial / Dose	Mean Weight Change	vs. Placebo	≥5% Weight Loss	≥20% Weight Loss
SURMOUNT-1 Placebo	−3.1%	—	34.4%	1.5%
SURMOUNT-1 — 5 mg	−15.0%	−11.9 pp	85.1%	30.5%
SURMOUNT-1 — 10 mg	−19.5%	−16.4 pp	89.7%	50.1%
SURMOUNT-1 — 15 mg	−20.9%	−17.8 pp	89.5%	55.8%
SURMOUNT-2 — 10 mg (T2D)	−13.4%	−10.1 pp	79.4%	25.8%
SURMOUNT-2 — 15 mg (T2D)	−15.7%	−12.4 pp	82.8%	36.2%

5.5 Weight Maintenance — SURMOUNT-4

SURMOUNT-4 (Aronne et al., 2024) enrolled participants who had completed a 36-week open-label run-in on tirzepatide 10 or 15 mg and randomized them to continue tirzepatide or switch to placebo for a further 52 weeks. Participants who continued tirzepatide lost an additional ~5.5% of body weight; those switched to placebo regained approximately 14.0% of body weight over the 52-week extension period [5]. This finding is consistent with the class-wide pattern of pharmacological dependence observed across GLP-1R agonist and dual incretin co-agonist trials and carries direct implications for long-term treatment strategy.

5.6 Safety and Tolerability

The safety profile of tirzepatide across the SURPASS and SURMOUNT programs is consistent with the established GLP-1 receptor agonist class profile.

Table 6 — Common Adverse Events in SURMOUNT-1 at 72 Weeks (Jastreboff et al., 2022)
Adverse Event	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg	Placebo
Nausea	30.4%	32.0%	33.2%	6.1%
Diarrhea	20.8%	21.8%	22.0%	10.3%
Constipation	20.8%	16.9%	17.8%	8.9%
Vomiting	12.3%	13.9%	13.3%	2.4%
AEs leading to discontinuation	5.0%	7.1%	6.2%	2.6%

Consistent with the GLP-1 agonist class, gastrointestinal adverse events were predominantly mild to moderate in severity and associated with the dose-escalation period. Class-level safety considerations for GLP-1 receptor agonists — including thyroid C-cell effects observed in rodent carcinogenicity studies and contraindication in patients with a personal or family history of medullary thyroid carcinoma or MEN2 — apply to tirzepatide. Pancreatitis was reported at low rates in both SURMOUNT and SURPASS trials, consistent with class-level rates observed across the GLP-1 agonist landscape.

6. Evidence Status

Table 7 — Tirzepatide Evidence Hierarchy by Development Stage
Evidence Type	Current Status
Phase 3 T2D (SURPASS program)	Published across multiple peer-reviewed journals (2021–2022)
Phase 3 obesity (SURMOUNT program)	Published (SURMOUNT-1: NEJM 2022; SURMOUNT-2: Lancet 2023; SURMOUNT-4: JAMA 2024)
Cardiovascular outcomes trial (SURPASS-CVOT)	Ongoing; peer-reviewed results not yet available as of this article’s last review date
FDA approval — T2D (Mounjaro)	Approved May 2022
FDA approval — Obesity (Zepbound)	Approved November 2023
Long-term safety surveillance (>72 weeks)	Post-marketing; ongoing accumulation
Mechanistic basis of GIPR weight loss contribution	Under investigation; not definitively established

What We Still Don’t Know

Cardiovascular outcomes in high-risk populations: SURPASS-CVOT is ongoing; whether tirzepatide reduces MACE in T2D patients with established cardiovascular disease has not been confirmed in a dedicated CV outcomes trial as of this article’s last review date.
Why GIPR agonism enhances weight loss: The mechanistic contribution of GIPR co-activation to the weight outcomes observed with tirzepatide — relative to GLP-1R monoagonism — is not definitively understood at the receptor, tissue, or systems level.
Long-term consequences of GIPR agonism in humans: Unlike GLP-1R, which has been studied in humans for over two decades, the long-term effects of sustained GIPR agonism at pharmacological doses have a shorter clinical history.
Weight regain after discontinuation: SURMOUNT-4 demonstrated substantial weight regain, but the trajectory beyond 52 weeks post-discontinuation and whether partial weight maintenance occurs have not been reported.
Performance in diverse populations: Trial populations were predominantly white adults; generalizability across racial, ethnic, and age subgroups requires further study.

Although tirzepatide has received regulatory approval, the precise biological contribution of GIPR agonism to its clinical effects remains incompletely understood.

7. Limitations of Current Research

Cardiovascular Outcomes Trial Pending A dedicated cardiovascular outcomes trial (SURPASS-CVOT) was ongoing as of this article’s last review date. The directionally favorable MACE hazard ratio in SURPASS-4 (HR 0.74) did not reach statistical significance, as that trial was powered for glycemic outcomes rather than CV events. Whether tirzepatide reduces MACE in high-risk populations has not been established in a dedicated, adequately powered cardiovascular outcomes trial.

Mechanistic Contribution of GIPR Agonism Unresolved The observation that dual GIPR/GLP-1R co-agonism produces greater weight loss than GLP-1R monoagonism remains mechanistically unexplained at the human level. Proposed mechanisms — including GIPR-mediated adipose tissue effects, central nervous system amplification, and altered gastric motility — are supported by preclinical data but have not been isolated or quantified in controlled human experiments.

Treatment Dependence — Weight Regain on Discontinuation SURMOUNT-4 demonstrated that participants who discontinued tirzepatide after 36 weeks regained approximately 14.0% of body weight over the subsequent 52 weeks. Published data indicate substantial attenuation of treatment effects following discontinuation, consistent with the class-level pattern across GLP-1R agonist pharmacology, and with significant implications for long-term treatment strategy and cost-effectiveness modeling.

Reduced Weight Loss in T2D Populations SURMOUNT-2, which enrolled adults with T2D and obesity, showed smaller absolute weight reductions than SURMOUNT-1 (−13.4% and −15.7% vs. −19.5% and −20.9% at comparable doses). This population-level difference is consistent with findings across GLP-1 receptor agonist trials and is not fully mechanistically explained.

Head-to-Head Comparisons with Higher-Dose Semaglutide SURPASS-2 compared tirzepatide with semaglutide 1 mg (the T2D dose) rather than the 2.4 mg obesity dose. No published direct head-to-head trial has compared tirzepatide with semaglutide 2.4 mg or with retatrutide in comparable populations. Inferring relative efficacy from cross-trial comparisons is unreliable due to population and protocol differences.

Long-Term Safety Profile Although tirzepatide has accumulated post-marketing safety data since 2022, the longest randomized clinical trial follow-up is 72–88 weeks. Long-term data on thyroid C-cell effects in humans, pancreatic safety beyond trial windows, and the consequences of decade-length continuous GIPR agonism in diverse patient populations remain to be established through post-marketing surveillance and longer-duration studies.

Population Generalizability The SURMOUNT trials enrolled predominantly white adults with access to academic clinical centers. Generalizability across racial and ethnic populations, age groups outside the enrolled ranges, and patients with complex comorbidities or concomitant medications requires further investigation in real-world and diverse clinical populations.

In Vitro Research Context In vitro applications of tirzepatide — including GIPR and GLP-1R binding assays, cAMP accumulation studies, biased agonism characterization, and downstream signaling pathway analysis — are conducted under conditions that do not replicate the albumin- binding, pharmacokinetic, and tissue distribution environment of human systemic administration. The imbalanced receptor potency profile observed in vitro does not directly predict the relative contribution of each receptor to in vivo clinical outcomes.

⚠ Research and Informational Use Only. All content on this page is for informational and educational purposes and is intended for qualified research professionals. Nothing on this page constitutes medical advice, diagnosis, or treatment guidance. Tirzepatide is supplied by Wholesale Peps as lyophilized powder for in vitro laboratory research only and is not approved by the FDA for human or veterinary use. Read full disclaimer →

References

Willard FS, Douros JD, Gabe MBN, et al. "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight. 2020;5(17):e140532. doi:10.1172/jci.insight.140532
Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." New England Journal of Medicine. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
Garvey WT, Frias JP, Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)." The Lancet. 2023;402(10402):613–626. doi:10.1016/S0140-6736(23)01200-X
Aronne LJ, Sattar N, Horn DB, et al. "Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity." JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945
Del Prato S, Kahn SE, Pavo I, et al. "Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel group, multicentre, phase 3 trial." The Lancet. 2021;398(10313):1811–1824. doi:10.1016/S0140-6736(21)02188-7